Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tariq H. Iqbal, Nicholas Kennedy, Anjan Dhar, Waqas Ahmed & Richard F. Pollock. (2024) Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of Medical Economics 27:1, pages 392-403.
Read now
Read now
Ozra Tabasi, Mahdi Roohi Razlighi & Cavus Falamaki. (2023) A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization. Journal of Carbohydrate Chemistry 42:1-3, pages 1-39.
Read now
Read now
Xenophon Kassianides, Richard Bodington & Sunil Bhandari. (2021) An evaluation of ferric derisomaltose as a treatment for anemia. Expert Review of Hematology 14:1, pages 7-29.
Read now
Read now
Richard F. Pollock & Patrick Biggar. (2020) Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Review of Hematology 13:2, pages 187-195.
Read now
Read now
Charlotte Holm, Lars L. Thomsen & Jens Langhoff-Roos. (2019) Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. The Journal of Maternal-Fetal & Neonatal Medicine 32:17, pages 2797-2804.
Read now
Read now
Jürgen Stein, Andreas Walper, Wolfgang Klemm, Karima Farrag, Ayşegül Aksan & Axel Dignass. (2018) Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scandinavian Journal of Gastroenterology 53:9, pages 1059-1065.
Read now
Read now
Articles from other publishers (23)
Tahir Aslam & Asim Mehmood. (2023) Prevalence and Risk Factors of Anemia in Inflammatory Bowel Diseases: A Case-Control Study. Cureus.
Crossref
Crossref
Ishan P Shah, Manish Pandya, Bhamini Kadikar, Pankaj Nimbalkar & Tejas Patel. (2023) A prospective interventional study to observe the effectiveness of parenteral iron infusion of iron isomaltoside 1000 (Fur – IV) in obstetrics and gynecology patients suffering from moderate to severe iron deficiency anaemia. Indian Journal of Obstetrics and Gynecology Research 10:2, pages 110-114.
Crossref
Crossref
Edyta Tulewicz-Marti, Paulina Szwarc, Martyna Więcek, Konrad Lewandowski, Tomasz Korcz, Malgorzata Cicha & G. Rydzewska. (2023) Effect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel Disease—Results of a Prospective Single-Centre Study. Journal of Personalized Medicine 13:3, pages 458.
Crossref
Crossref
Laura A. Maas, Mahesh Krishna & Alyssa M. Parian. (2022) Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences 68:2, pages 357-369.
Crossref
Crossref
Johannes M. M. Boots & Rogier A. M. Quax. (2022) High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment. Drug Safety 45:10, pages 1019-1036.
Crossref
Crossref
R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova & I. Yu. Torshin. (2022) Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:1, pages 73-86.
Crossref
Crossref
Rocco SPAGNUOLO, Ludovico ABENAVOLI, Tiziana LARUSSA, Chiara IANNELLI, Rinaldo PELLICANO, Sharmila FAGOONEE, Patrizia DOLDO & Francesco LUZZA. (2022) Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview. Minerva Gastroenterology 68:1.
Crossref
Crossref
Jackie Kearns & Sudheer George Jacob. (2021) Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders. Frontline Gastroenterology 12:4, pages 265-271.
Crossref
Crossref
Benedikt Schaefer, Moritz Tobiasch, André Viveiros, Herbert Tilg, Nicholas A. Kennedy, Myles Wolf & Heinz Zoller. (2020) Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis. British Journal of Clinical Pharmacology 87:5, pages 2256-2273.
Crossref
Crossref
Sunil Bhandari, Philip A Kalra, Mario Berkowitz, Diogo Belo, Lars L Thomsen & Myles Wolf. (2021) Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrology Dialysis Transplantation 36:1, pages 111-120.
Crossref
Crossref
Wendy Fang, Rachel Kenny, Qurat-ul-Ain Rizvi, Lawrence P. McMahon & Mayur Garg. (2020) Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status. BMC Gastroenterology 20:1.
Crossref
Crossref
Frank Loughnane, Gorden Muduma & Richard F. Pollock. (2020) Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. Advances in Therapy 37:3, pages 1218-1232.
Crossref
Crossref
Myles Wolf, Janet Rubin, Maureen Achebe, Michael J. Econs, Munro Peacock, Erik A. Imel, Lars L. Thomsen, Thomas O. Carpenter, Thomas Weber, Vincent Brandenburg & Heinz Zoller. (2020) Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA 323:5, pages 432.
Crossref
Crossref
Michael Auerbach, David Henry, Richard J. Derman, Maureen M. Achebe, Lars L. Thomsen & John Glaspy. (2019) A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial. American Journal of Hematology 94:9, pages 1007-1014.
Crossref
Crossref
Richard F. Pollock & Gorden Muduma. (2019) Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy 36:8, pages 1821-1825.
Crossref
Crossref
Sunil Bhandari, Dora Pereira, Helen Chappell & Hal Drakesmith. (2018) Intravenous Irons: From Basic Science to Clinical Practice. Pharmaceuticals 11:3, pages 82.
Crossref
Crossref
Mikkel Gybel‐Brask, Jens Seeberg, Lars L. ThomsenPär I. Johansson. (2018) Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron‐deficient blood donors: a randomized double‐blind placebo‐controlled clinical trial. Transfusion 58:4, pages 974-981.
Crossref
Crossref
Dhruvan Patel, Chinmay Trivedi & Nabeel Khan. (2018) Management of Anemia in Patients with Inflammatory Bowel Disease (IBD). Current Treatment Options in Gastroenterology 16:1, pages 112-128.
Crossref
Crossref
Francesc Casellas Jordá, Isabel Vera Mendoza, Manuel Barreiro-de Acosta, Juan María Vázquez Morón, Javier López Román & Javier Júdez Gutiérrez. (2018) Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the Gestiona hierro-EII survey. Revista Española de Enfermedades Digestivas 110.
Crossref
Crossref
Katarzyna Muras-Szwedziak & Michal Nowicki. (2018) Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5. Kidney and Blood Pressure Research 43:1, pages 143-151.
Crossref
Crossref
Louis L Huang, Darren Lee, Stefanie M Troster, Annette B Kent, Matthew A Roberts, Iain C Macdougall & Lawrence P McMahon. (2017) A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrology Dialysis Transplantation.
Crossref
Crossref
Richard Derman, Eloy Roman, Manuel R. Modiano, Maureen M. Achebe, Lars L. Thomsen & Michael Auerbach. (2017) A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. American Journal of Hematology 92:3, pages 286-291.
Crossref
Crossref
Svein Oskar Frigstad, Anne Haaber, Antal Bajor, Jan Fallingborg, Per Hammarlund, Ole K. Bonderup, Håkan Blom, Terje Rannem & Per M. Hellström. (2017) The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency. Gastroenterology Research and Practice 2017, pages 1-7.
Crossref
Crossref